News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
516,959 Results
Type
Article (44181)
Company Profile (130)
Press Release (472648)
Section
Business (144703)
Career Advice (2379)
Deals (27878)
Drug Delivery (106)
Drug Development (67741)
Employer Resources (148)
FDA (15541)
Job Trends (11928)
News (263142)
Policy (29548)
Tag
Academia (2282)
Alliances (35698)
Alzheimer's disease (1278)
Approvals (15441)
Artificial intelligence (115)
Bankruptcy (300)
Best Places to Work (9104)
Biotechnology (82)
Breast cancer (108)
Cancer (977)
Cardiovascular disease (85)
Career advice (1987)
Cell therapy (222)
Clinical research (53575)
Collaboration (315)
Compensation (188)
COVID-19 (2544)
C-suite (85)
Data (954)
Diabetes (149)
Diagnostics (5079)
Drug pricing (97)
Earnings (57120)
Employer resources (136)
Events (74520)
Executive appointments (240)
FDA (16030)
Funding (262)
Gene therapy (176)
GLP-1 (638)
Government (3791)
Healthcare (14687)
Infectious disease (2627)
Inflammatory bowel disease (99)
Interviews (444)
IPO (13778)
Job creations (3152)
Job search strategy (1660)
Layoffs (450)
Legal (6901)
Lung cancer (161)
Manufacturing (164)
Medical device (11049)
Medtech (11052)
Mergers & acquisitions (14148)
Metabolic disorders (423)
Neuroscience (1531)
NextGen Class of 2024 (4970)
Non-profit (3155)
Northern California (1283)
Obesity (251)
Opinion (187)
Patents (96)
People (41752)
Phase I (15963)
Phase II (23189)
Phase III (19099)
Pipeline (437)
Policy (83)
Postmarket research (2192)
Preclinical (6469)
Radiopharmaceuticals (200)
Rare diseases (207)
Real estate (4247)
Regulatory (20167)
Research institute (2048)
Resumes & cover letters (400)
Southern California (1112)
Startups (2735)
United States (11288)
Vaccines (618)
Weight loss (209)
Date
Last 7 days (853)
Last 30 days (3164)
Last 365 days (31377)
2024 (28487)
2023 (34986)
2022 (45062)
2021 (48503)
2020 (45517)
2019 (36210)
2018 (27399)
2017 (27805)
2016 (25805)
2015 (27975)
2014 (21775)
2013 (17793)
2012 (18963)
2011 (19382)
2010 (17512)
Location
Africa (667)
Arizona (136)
Asia (30454)
Australia (5329)
California (2801)
Canada (930)
China (175)
Colorado (123)
Connecticut (138)
Europe (73923)
Florida (397)
Georgia (95)
Illinois (256)
Indiana (148)
Maryland (523)
Massachusetts (2226)
Michigan (118)
Minnesota (213)
New Jersey (818)
New York (799)
North Carolina (629)
Northern California (1283)
Ohio (105)
Pennsylvania (711)
South America (1031)
Southern California (1112)
Texas (370)
Washington State (315)
516,959 Results for "genmab a s".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
FDA
Pfizer, Genmab’s ADC Tivdak Scores Full FDA Approval in Recurrent or Metastatic Cervical Cancer
Based on strong overall and progression-free survival data in its Phase III confirmatory study, Pfizer and Genmab’s antibody-drug conjugate Tivdak on Monday secured the FDA’s full approval for recurrent or metastatic cervical cancer that had progressed on or after chemotherapy.
April 30, 2024
·
2 min read
·
Tristan Manalac
Approvals
AbbVie, Genmab Secure European Label Expansion for Tepkinly in Follicular Lymphoma
Two months after winning FDA approval in the same indication, AbbVie and Genmab on Monday secured the European Commission’s nod for its bispecific antibody Tepkinly for the most common type of low-grade non-Hodgkin lymphoma.
August 20, 2024
·
2 min read
·
Tristan Manalac
Deals
Genmab Completes Acquisition of ProfoundBio
Genmab A/S announced that it has completed its acquisition of ProfoundBio, Inc., a clinical-stage biotechnology company developing next-generation antibody-drug conjugates s and ADC technologies for the treatment of cancers in an all-cash transaction of USD 1.8 billion.
May 21, 2024
·
5 min read
Press Releases
Genmab to Present at Jefferies London Healthcare Conference
November 5, 2024
·
3 min read
FDA
AbbVie, Genmab Secure FDA Label Expansion for Epkinly in Follicular Lymphoma
AbbVie and Genmab on Wednesday announced the FDA has expanded the label of their bispecific antibody Epkinly, allowing it to be used in patients with relapsed or refractory follicular lymphoma.
June 27, 2024
·
2 min read
·
Tristan Manalac
BioForest
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
Genmab A/S and ProfoundBio, Inc. announced that the companies have entered into a definitive agreement for Genmab to acquire ProfoundBio in an all-cash transaction.
April 3, 2024
·
8 min read
Press Releases
Genmab Announces Financial Results for the First Nine Months of 2024
November 6, 2024
·
6 min read
Genmab Announces Financial Results for the First Quarter of 2024
Genmab announces Interim Report for the First Quarter Ended March 31, 2024.
May 2, 2024
·
7 min read
Genmab Publishes 2023 Annual Report
Genmab A/S announced the publication of its Annual Report for 2023.
February 14, 2024
·
9 min read
Press Releases
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024
October 15, 2024
·
3 min read
1 of 51,696
Next
